IDH1 and astrocytoma (excluding glioblastoma): Our data support the notion that increased genome-wide DNA methylation levels are associated with improved outcome in this tumour type and indicate that the type of IDH1/2 mutation should be taken into account for prognostication of astrocytoma patients.